Neoplasms Metastatic to the Larynx: A Systematic Review.

IF 3.4 Q2 ONCOLOGY

Oncology and Therapy Pub Date : 2026-09-18 DOI:10.1007/s40487-026-00466-3

Claudia Montenegro, Fatima-Ezzahra Nassih, Cesare Piazza, Alfio Ferlito

{"title":"Neoplasms Metastatic to the Larynx: A Systematic Review.","authors":"Claudia Montenegro, Fatima-Ezzahra Nassih, Cesare Piazza, Alfio Ferlito","doi":"10.1007/s40487-026-00466-3","DOIUrl":null,"url":null,"abstract":"Introduction: Metastatic involvement of the larynx from nonhead and neck primary tumors is an exceptionally rare event, frequently misdiagnosed as a primary laryngeal lesion and at risk of inappropriately aggressive surgical management. This systematic review aimed to define the most common primary sources, clinical features, diagnostic workup, treatment, and survival outcomes of tumors metastatic to the larynx from distant sites.Methods: A comprehensive search of PubMed, Web of Science, and Scopus identified original English-language reports published between 1984 and 2026, screened independently by two reviewers according to Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) recommendations.Results: A total of 83 articles were included, comprising 113 patients with histologically confirmed laryngeal metastases; the evidence consisted exclusively of single case reports and small retrospective series. Patients were predominantly older men with a mean age of 63.6 years. The most frequent primary site was the prostate (26.5%), followed by kidney (18.6%), colorectum (14.2%), skin melanoma (13.3%), lung (8.8%), and breast (6.2%). The supraglottis was the most commonly involved subsite, and the cartilaginous framework was affected in nearly one-quarter of cases. The median interval between primary diagnosis and laryngeal metastasis was 36 months, although the laryngeal lesion preceded or coincided with the primary in roughly one-fifth of patients. Hoarseness, dyspnea or stridor, and dysphagia were the dominant symptoms, clinically indistinguishable from primary laryngeal tumors. Treatment was heterogeneous and largely conservative or palliative, and overall survival was generally measured in months.Conclusions: Laryngeal metastasis should be suspected whenever a laryngeal mass arises in a patient with a known or suspected extralaryngeal malignancy, prompting whole-body staging before biopsy and a multidisciplinary, individualized management strategy.","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology and Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40487-026-00466-3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Metastatic involvement of the larynx from nonhead and neck primary tumors is an exceptionally rare event, frequently misdiagnosed as a primary laryngeal lesion and at risk of inappropriately aggressive surgical management. This systematic review aimed to define the most common primary sources, clinical features, diagnostic workup, treatment, and survival outcomes of tumors metastatic to the larynx from distant sites.

Methods: A comprehensive search of PubMed, Web of Science, and Scopus identified original English-language reports published between 1984 and 2026, screened independently by two reviewers according to Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) recommendations.

Results: A total of 83 articles were included, comprising 113 patients with histologically confirmed laryngeal metastases; the evidence consisted exclusively of single case reports and small retrospective series. Patients were predominantly older men with a mean age of 63.6 years. The most frequent primary site was the prostate (26.5%), followed by kidney (18.6%), colorectum (14.2%), skin melanoma (13.3%), lung (8.8%), and breast (6.2%). The supraglottis was the most commonly involved subsite, and the cartilaginous framework was affected in nearly one-quarter of cases. The median interval between primary diagnosis and laryngeal metastasis was 36 months, although the laryngeal lesion preceded or coincided with the primary in roughly one-fifth of patients. Hoarseness, dyspnea or stridor, and dysphagia were the dominant symptoms, clinically indistinguishable from primary laryngeal tumors. Treatment was heterogeneous and largely conservative or palliative, and overall survival was generally measured in months.

Conclusions: Laryngeal metastasis should be suspected whenever a laryngeal mass arises in a patient with a known or suspected extralaryngeal malignancy, prompting whole-body staging before biopsy and a multidisciplinary, individualized management strategy.

查看原文本刊更多论文

肿瘤转移到喉部：一个系统的回顾。

摘要：非头颈部原发肿瘤转移至喉部是非常罕见的，常被误诊为喉部原发病变，且存在手术治疗不当的风险。本系统综述旨在确定肿瘤从远处转移到喉部的最常见的主要来源、临床特征、诊断检查、治疗和生存结果。方法：综合检索PubMed、Web of Science和Scopus，确定了1984年至2026年间发表的原始英语报告，由两位审稿人根据系统评价和荟萃分析（PRISMA）推荐的首选报告项目独立筛选。结果：共纳入83篇文献，包括113例组织学证实的喉部转移患者；证据仅包括单个病例报告和小型回顾性系列。患者以老年男性为主，平均年龄63.6岁。最常见的原发部位是前列腺（26.5%），其次是肾脏（18.6%）、结直肠（14.2%）、皮肤黑色素瘤（13.3%）、肺（8.8%）和乳腺（6.2%）。声门上是最常见的受累部位，软骨框架在近四分之一的病例中受到影响。原发性诊断和喉部转移之间的中位间隔为36个月，尽管在大约五分之一的患者中喉部病变先于或与原发性病变同时发生。声音嘶哑、呼吸困难或喘鸣、吞咽困难是主要症状，临床上与原发性喉部肿瘤难以区分。治疗是异质性的，主要是保守或姑息性的，总体生存期通常以月为单位。结论：当已知或疑似咽外恶性肿瘤的患者出现喉部肿块时，应怀疑喉转移，在活检前应进行全身分期，并采取多学科、个性化的治疗策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncology and Therapy ONCOLOGY-

CiteScore

3.40

自引率

0.00%

发文量

审稿时长

6 weeks

期刊介绍： Now indexed in PubMed Aims and Scope Oncology and Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality pre-clinical, clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Oncology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research. Rapid Publication The journal’s rapid publication timelines aim for a peer review decision within 2 weeks of submission. If an article is accepted it will be published online 3-4 weeks from acceptance. These rapid timelines are achieved through the combination of a dedicated in-house editorial team, who closely manage article workflow, and an extensive Editorial and Advisory Board who assist with rapid peer review. This allows the journal to support the rapid dissemination of research, whilst still providing robust peer review. Combined with the journal’s open access model this allows for the rapid and efficient communication of the latest research and reviews, allowing the advancement of clinical therapies. Personal Service The journal’s dedicated in-house editorial team offer a personal “concierge service” meaning that authors will always have a personal point of contact able to update them on the status of their manuscript. The editorial team check all manuscripts to ensure that articles conform to the most recent COPE, GPP and ICMJE publishing guidelines. This supports the publication of ethically sound and transparent research. We also encourage pre-submission enquiries and are always happy to provide a confidential assessment of manuscripts. Digital features and plain language summaries Oncology and Therapy offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by key summary points, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article. The journal also provides the option to include various types of digital features including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations. All additional features are peer reviewed to the same high standard as the article itself. If you consider that your paper would benefit from the inclusion of a digital feature, please let us know. Our editorial team are able to create high-quality slide decks and infographics in-house, and video abstracts through our partner Research Square, and would be happy to assist in any way we can. For further information about digital features, please contact the journal editor (see ‘Contact the Journal’ for email address), and see the ‘Guidelines for digital features and plain language summaries’ document under ‘Submission guidelines’. Preprints We encourage posting of preprints of primary research manuscripts on preprint servers, authors'' or institutional websites, and open communications between researchers whether on community preprint servers or preprint commenting platforms. Posting of preprints is not considered prior publication and will not jeopardize consideration in our journals. Please see here for further information on preprint sharing: https://www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/submission/1302#c16721550 Peer Review Process Upon submission, manuscripts are assessed by the editorial team to ensure they fit within the aims and scope of the journal and are also checked for plagiarism. All suitable submissions are then subject to a comprehensive single-blind peer review. Reviewers are selected based on their relevant expertise and publication history in the subject area. The journal has an extensive pool of editorial and advisory board members who have been selected to assist with peer review based on the afore-mentioned criteria. At least two extensive reviews are required to make the editorial decision, with the exception of some article types such as Commentaries, Editorials and Letters which are generally reviewed by one member of the Editorial Board. Where reviewer recommendations are conflicted, the editorial board will be contacted for further advice and a presiding decision. Manuscripts are then either accepted, rejected or authors are required to make major or minor revisions (both reviewer comments and editorial comments may need to be addressed). Once a revised manuscript is re-submitted, it is assessed along with the responses to reviewer comments and if it has been adequately revised it will be accepted for publication. Accepted manuscripts are then copyedited and typeset by the production team before online publication. Appeals against decisions following peer review are considered on a case by case basis and should be sent to the journal editor. Copyright Oncology and Therapy''s content is published open access under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, click here: http://creativecommons.org/licenses/by-nc/4.0 Publication Fees Upon acceptance of an article, authors will be required to pay the mandatory Rapid Service Fee of £3650/€4500/$5100. The journal will consider fee discounts for developing countries and this is decided on a case by case basis. Open Access All articles published by Oncology and Therapy are published open access Contact For more information about the journal, including pre-submission enquiries, please contact managing editor Lydia Alborn at lydia.alborn@springer.com.